Biotech Firm Initiates Human Trials for Cellular Ageing Reversal
This digest was compiled by AI from multiple sources — links to the originals are below.
A biotech firm is set to begin human trials aimed at reversing cellular ageing. The trials will assess the safety and efficacy of rejuvenating aged tissues and organs. This development comes amid growing interest in anti-ageing technologies.
Clinical Trial Details
The clinical trial will be conducted by a leading biotech firm, targeting the reversal of cellular ageing. The trial will involve a cohort of participants to evaluate the potential for rejuvenating aged tissues. Researchers aim to determine the safety and effectiveness of the method, with results expected to influence future anti-ageing therapies.
Scientific Community's Response
The scientific community has shown keen interest in the trial, with institutions like the National Institutes of Health monitoring developments. The trial's outcome could impact the broader field of regenerative medicine. Experts are cautious but optimistic about the potential breakthrough in extending healthy human lifespan.
CureVac COVID-19 Vaccine Trial
CureVac, a German biotech firm, initiated human trials of an experimental COVID-19 vaccine, becoming the second company after BioNTech to do so in Germany. The company aims for regulatory approval by mid-2021.
What's Next
The trial is expected to commence in the coming months, with initial results anticipated by year-end. It remains unclear how the findings will influence regulatory approval and commercial applications.
2 sources
Biotech Firm Initiates Human Trials for Cellular Ageing Reversal
